Is a surgery in your pet's future? If it is, you probably have a few questions about pre- and post-surgery care. Paying close attention to care recommendations will help you ensure that the surger ...View Article
You are using an outdated browser. Please upgrade your browser to improve your experience.
TANOVEA-CA1 (Lymphoma Treatment)
Maine Veterinary Medical Center's Oncology Department is thrilled to offer Tanovea-CA1, the first ever FDA conditionally approved lymphoma treatment for dogs. MVMC offers a number of drugs to treat canine lymphoma and is excited to offer the most recent development.
Lymphoma, also known as lymphoscaroma is a type of cancer affecting canines. The active ingredient in Tanovea-CA1, rabacfosadine, is a substance that kills rapidly growing lymphoma cancer cells.
If you have any questions regarding the drug or patients that may be eligible, please contact us.
How does TANOVEA-CA1 work?
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.